S-8

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

As filed with the Securities and Exchange Commission on August 10, 2020

Registration No. 333-

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

Adverum Biotechnologies, Inc.

(Exact name of Registrant as specified in its charter)

Delaware

20-5258327

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification Number)

800 Saginaw Drive

Redwood City, California 94063

(Address, including zip code, of Registrant’s principal executive offices)

2017 Inducement Plan, as amended and restated

(Full title of the plan)

Peter Soparkar

Chief Legal Officer

Adverum Biotechnologies, Inc.

800 Saginaw Drive

Redwood City, California 94063

(650) 656-9323

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Kenneth Guernsey

Cooley LLP

101 California Street, 5th Floor

San Francisco, CA 94111-5800

(415) 693-2000

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

CALCULATION OF REGISTRATION FEE



Title of Securities to be Registered	Amount to be Registered(1)	Proposed Maximum Offering Price Per Share(3)	Proposed Maximum Aggregate Offering Price	Amount of Registration Fee
Common Stock, par value $0.0001 per share	1,500,000 shares (2)	$17.71	$26,565,000.00	$3,448.14

(1)

Pursuant to Rule 416 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the Registrant’s Common Stock that become issuable under the plan set forth herein by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of the Registrant’s Common Stock.

(2)	Represents shares of Common Stock that were added to the shares reserved for issuance under the Registrant’s 2017 Inducement Plan, as amended and restated, on June 17, 2020.

(3)

Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) and Rule 457(c) promulgated under the Securities Act. The offering price per share and the aggregate offering price are based upon the average of the high and low prices of the Registrant’s Common Stock as reported on The Nasdaq Global Market on August 4, 2020.

Explanatory Note

This Registration Statement on Form S-8 (this “Registration Statement”) registers 1,500,000 shares of the common stock, par value $0.0001 per share, of Adverum Biotechnologies, Inc. (“Common Stock”) that may be issued and sold under the Adverum Biotechnologies, Inc. 2017 Inducement Plan, as amended and restated (the “Plan”).

Pursuant to General Instruction E of Form S-8, this registration statement incorporates by reference the contents of the registration statements on Form S-8 relating to the Plan filed by the Registrant with the Securities and Exchange Commission (the “SEC”) on October 11, 2017 (File No. 333-220894), March 7, 2019 (as amended by Post-Effective Amendment No. 1 thereto filed on March 12, 2019, File No. 333-230138), and August 8, 2019 (File No. 333-233135).

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference.

The following documents have been filed by us with the SEC and are incorporated herein by reference:

•

The contents of the earlier registration statements on Form S-8 relating to the Plan, previously filed with the SEC on October 11, 2017 (File No. 333-220894), March 7, 2019 (as amended by Post-Effective Amendment No. 1 thereto filed on March 12, 2019, File No. 333-230138), and August 8, 2019 (File No. 333-233135);

•

our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the SEC on March 12, 2020 (our “Annual Report”), including the information incorporated by reference in the Form 10-K by our proxy statement for our 2020 Annual Meeting of Stockholders;

•

our quarterly reports on Form 10-Q for the quarters ended March 31, 2020 and June 30, 2020, which were filed with the SEC on May 28, 2020 and August 10, 2020, respectively.

•

our Current Reports on Form 8-K filed with the SEC on February 12, 2020 (other than the information furnished pursuant to Item 2.02 of such report), April 20, 2020, May 8, 2020, June 15, 2020 and June 29, 2020; and

•

the description of our common stock contained in our Registration Statement on Form 8-A filed with the SEC on July 28, 2014, including any amendments or reports filed for the purpose of updating such description, including Exhibit 4.3 to our Annual Report.

All documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items, prior to the filing of a post-effective amendment to this Registration Statement which indicates that all of the shares of Common Stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents.

For purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

Item 8. Exhibits.

Exhibit Index

Incorporated by Reference

Exhibit
Number

Exhibit Description

Form

SEC File

No.

Exhibit
Number

Date

Filed
Herewith

4.1

Amended and Restated Certificate of Incorporation.

10-K

001-36579

3.1

March 9, 2017

4.2

Amended and Restated Bylaws.

8-K

001-36579

3.1

June 29, 2020

4.3

Form of Common Stock Certificate.

S-1/A

333-197133

4.1

July 25, 2014

5.1

Opinion of Cooley LLP.

23.1

Consent of Independent Registered Public Accounting Firm.

23.2

Consent of Cooley LLP (included in Exhibit 5.1).

24.1

Power of Attorney (included on signature page hereto).

99.1

2017 Inducement Plan, as amended and restated.

10-Q

001-36579

10.9

August 10, 2020

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Redwood City, State of California on August 10, 2020.


Adverum Biotechnologies, Inc.

By:		/s/ Laurent Fischer, M.D.
		Laurent Fischer, M.D.
		Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Laurent Fischer, Leone Patterson and Thomas Leung, or any of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission (the “SEC”), and generally to do all such things in their names and behalf in their capacities as officers and directors to enable the registrant to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities indicated.


Signature	Title	Date

/s/ Laurent Fischer, M.D.	Chief Executive Officer and Director	August 10, 2020
Laurent Fischer, M.D.	(Principal Executive Officer)

/s/ Thomas Leung	Chief Financial Officer	August 10, 2020
Thomas Leung	(Principal Financial and Accounting Officer)

/s/ Patrick Machado	Board Chair, Director	August 10, 2020
Patrick Machado

/s/ Eric G. Carter, M.D., Ph.D.	Director	August 10, 2020
Eric G. Carter, M.D., Ph.D.

/s/ Mehdi Gasmi, Ph.D.	Director	August 10, 2020
Mehdi Gasmi, Ph.D.

/s/ Rekha Hemrajani	Director	August 10, 2020
Rekha Hemrajani

/s/ Mark Lupher, Ph.D.	Director	August 10, 2020
Mark Lupher, Ph.D.

/s/ James Scopa	Director	August 10, 2020
James Scopa

/s/ Scott Whitcup, M.D.	Director	August 10, 2020
Scott Whitcup, M.D.

/s/ Thomas Woiwode, Ph.D.	Director	August 10, 2020
Thomas Woiwode, Ph.D.